A Phase 3 interventional study of Tenapanor and Placebo in Hyperphosphatemia, sponsored by Ardelyx. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-10.
Sponsored by Ardelyx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing tenapanor in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. tenapanor · Hyperphosphatemia.
Among the 13 studies testing tenapanor in Hyperphosphatemia, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 3, and was the 2nd registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →None of the 13 studies testing tenapanor in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2016.
This study's enrollment of 219 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 172 across the 13 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 2 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 6 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing tenapanor in Hyperphosphatemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat hyperphosphatemia in end-stage renal disease patients on hemodialysis (ESRD-HD). Subjects who qualify are randomized into the study will either receive 3 mg BID, 10 mg BID, or a titration regimen of tenapanor.
The study consists of a screening visit, a wash out period of up to 3 weeks, when existing phosphate lowering medication is withheld, an 8-week treatment period, in which all groups receive tenapanor, and a 4-week placebo-controlled, randomized withdrawal period, during which patients are re-randomized 1:1 to either remain on their current tenapanor treatment or placebo.
Depending on the increase in serum phosphate levels, subjects can be randomized 1,2, or 3 weeks after being taken off their phosphate lowering medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenapanor, 3mg BID (6mg total)
Drug: Tenapanor
Tenapanor, 10mg BID (20mg total)
Drug: Tenapanor
Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
Drug: Tenapanor
Placebo
Drug: Placebo
Also known as: RDX5791, AZD1722
Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms
Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period
Time frame: 4 weeks
Change in Serum Phosphate During 8-Week Treatment Period
Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set
Time frame: Baseline and 8 weeks
| Milestone | 3mg BID | 10mg BID | 30 mg Dose Titration | Randomized Withdrawal Period Placebo |
|---|---|---|---|---|
| Started | 74 | 73 | 72 | 0 |
| Completed | 57 | 54 | 53 | 0 |
| Not completed | 17 | 19 | 19 | 0 |
| Withdrew: Adverse event | 6 | 5 | 6 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 3 | 0 |
| Withdrew: Lack of efficacy | 2 | 5 | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 | 2 | 0 |
| Withdrew: Gi side effects | 1 | 4 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 |
| Withdrew: Other | 3 | 1 | 2 | 0 |
| Milestone | 3mg BID | 10mg BID | 30 mg Dose Titration | Randomized Withdrawal Period Placebo |
|---|---|---|---|---|
| Started | 25 | 23 | 34 | 82 |
| Completed | 24 | 22 | 32 | 74 |
| Not completed | 1 | 1 | 2 | 8 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period
| mg/dL | 3mg BID | 10mg BID | 30 mg Dose Titration | Placebo |
|---|---|---|---|---|
| Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms | — | — | 1.4 ± 0.23 | 0.6 ± 0.21 |
Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set
| mg/dL | 3mg BID | 10mg BID | 30 mg Dose Titration | Placebo |
|---|---|---|---|---|
| Change in Serum Phosphate During 8-Week Treatment Period | -1.1 ± 0.17 | -1.1 ± 0.17 | -1.1 ± 0.18 | — |
Collected over 12 weeks. The first 8 weeks were tenapanor only and during the last 4 weeks half of the tenapanor-treated patients from the first 8 weeks were randomized to receive placebo. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3mg BID | 1/74 (1.4%) | 1/74 (1.4%) | 22/74 (29.7%) |
| 10mg BID | 0/73 (0%) | 0/73 (0%) | 30/73 (41.1%) |
| 30 mg Dose Titration | 0/72 (0%) | 0/72 (0%) | 34/72 (47.2%) |
| Randomized Withdrawal Period Placebo | 0/82 (0%) | 0/82 (0%) | 7/82 (8.5%) |
| Event | 3mg BID | 10mg BID | 30 mg Dose Titration | Randomized Withdrawal Period Placebo |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 1/74 | 0/73 | 0/72 | 0/82 |
| Event | 3mg BID | 10mg BID | 30 mg Dose Titration | Randomized Withdrawal Period Placebo |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 22/74 | 30/73 | 34/72 | 7/82 |
This was a placebo-controlled randomized withdrawal study. All participants received drug during the first 8-weeks (no placebo) and then were randomized 1:1 to either remain on tenapanor dose or receive placebo.
| Age, Continuous(years) | 3mg BID | 10mg BID | Dose Titration | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 55.7 ± 11.49 | 57.4 ± 10.81 | 54.2 ± 10.87 | — | 55.8 ± 11.09 |
| Sex: Female, Male(Participants) | 3mg BID | 10mg BID | Dose Titration | Placebo | Total |
|---|---|---|---|---|---|
| Female | 28 | 39 | 24 | — | 91 |
| Male | 46 | 34 | 48 | — | 128 |
| Ethnicity (NIH/OMB)(Participants) | 3mg BID | 10mg BID | Dose Titration | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 8 | 19 | — | 40 |
| Not Hispanic or Latino | 61 | 65 | 53 | — | 179 |
| Unknown or Not Reported | 0 | 0 | 0 | — | 0 |
| Race (NIH/OMB)(Participants) | 3mg BID | 10mg BID | Dose Titration | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | — | 2 |
| Asian | 2 | 0 | 0 | — | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 1 | — | 4 |
| Black or African American | 40 | 45 | 40 | — | 125 |
| White | 30 | 25 | 31 | — | 86 |
| More than one race | 0 | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | — | 0 |
| Body Mass Index(m/kg^2) | 3mg BID | 10mg BID | Dose Titration | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 32.5 ± 8.52 | 33.6 ± 8.50 | 33.4 ± 8.15 | — | 33.1 ± 8.37 |
The record gives a start of Jan 2016, a primary completion of Dec 2016 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor